88 results about "Circadian rhythm" patented technology

The invention relates to the crossing field of computer technology and biomedical engineering, and discloses a miniaturized intelligent blood glucose monitoring and analyzing method integrating edge computing. The method comprises the steps that glucose concentration and time sequence multi-source physiological signals are collected through a wearable sensor; performing data segmentation and multi-modal feature alignment based on the circadian rhythm; inputting the features into a lightweight student model obtained through knowledge distillation for blood glucose prediction; and the reasoning frequency is adaptively adjusted in combination with a memory feedback mechanism. The system comprises a sensing unit, a preprocessing unit, a lightweight model execution unit and a risk early warning unit. While the prediction precision is guaranteed, the model is compressed to be within 150 thousand parameters, a 512 KB on-chip memory is adapted, and low-power-consumption and high-stability end-side continuous blood glucose monitoring and early warning are achieved.

This invention belongs to the technical field of sleep quality analysis, specifically relating to a sleep quality analysis system and method based on sensors in a medical bed, to address the technical problem of existing methods relying too heavily on duration statistics while neglecting the continuity and circadian rhythm of sleep. The analysis method includes: S1, acquiring vital sign signal data collected by sensors in the medical bed within a sleep cycle and dividing it into multiple continuous time segments; S2, extracting physiological indicators such as respiratory rate, heart rate, and body movement amplitude within each time segment, and calculating the variability depth of the corresponding time segment; S3, generating a variability depth baseline; calculating non-steady-state disturbance factors based on the frequency and duration of micro-awakening disturbance segments; and S4, generating a comprehensive sleep quality score. The analysis method of this invention improves the comprehensiveness and objectivity of the assessment results, more realistically reflecting sleep health status.

The purpose of the present disclosure is to provide a device and a method for easily deriving the sleep quality of a user.　In a server 100 of the present disclosure, a log acquisition unit 103 acquires log information of a portable terminal 200 (user terminal) which is used by a user. On the basis of the log information, an estimation unit 108 estimates a user situation (sleep time, terminal use situation immediately before bedtime, sleep environment, circadian rhythm, etc.) that affects sleeping. Then, the estimation unit 108 estimates (corresponding to deriving) the sleep quality of the user on the basis of the user situation.

The present invention provides a package of a micronutrient supplement for promoting the digestive function of the intestinal tract of a body, the micronutrient supplement consisting of two types of unit dosage forms in one package for sale to a purchaser wherein the first type of unit dosage form contains VB6 and a compound thereof, and the second type of unit dosage form contains VB6 and a compound thereof. The first type of unit dosage form contains Zn and compounds thereof, the second type of unit dosage form contains Zn and compounds thereof or VD and compounds thereof, and the first type of unit dosage form does not contain Zn and VD, and the second type of unit dosage form does not contain VB6, the micronutrient supplement being provided in a manner of administration twice a day, the first type of unit dosage form is taken in an awakening period, and the second type of unit dosage form is taken in a sleep period. The packaging product can be matched with the biological clock rhythm of an organism, the absorption and utilization rate of micronutrients is increased, and then the intestinal digestion function is improved.

The application relates to a compound medicine for delaying skeletal muscle aging and application thereof, and the medicinal active components in the compound medicine composition are composed of menadione bisulfite sodium and N-acetyl cysteine, and belong to the technical field of biological medicine. A novel drug combination mode is developed, an oxidant menadione bisulfite sodium (MBS) and an antioxidant N-acetyl-L-cysteine (NAC) are combined and given in different time periods to regulate the H2O2 circadian rhythm of the skeletal muscle of old mice, the changes of the muscle strength, histopathology and aging marker protein level of the skeletal muscle of the old mice are detected, and then the precise compound medicine capable of improving the skeletal muscle function of the old mice and delaying skeletal muscle aging is determined. The application provides an effective drug combination strategy for relieving or treating the delay of skeletal muscle aging, and has very significant meaning.

A testing device and testing method of a hydrocephalus shunt valve. It relates to the technical field of medical device testing. The long-term reliability and adaptability of the shunt valve can be simulated in a complex physiological environment. The testing device of the hydrocephalus shunt valve comprises a controller, a body position simulation device, an ICP pressure chamber, an IPP pressure chamber, a backflow pump, a flow sensor and a circulating pipeline. The body position simulation device comprises a support, a pair of long arms simulating the human torso and a pair of short arms simulating the human head and neck, and a motor one driving the pair of long arms to swing and a motor two driving the pair of short arms to swing. The present application combines the in-vitro hardware testing platform with different patient physiological models, can reproduce physiological characteristics such as basic body position posture change, body temperature circadian rhythm fluctuation and long-term applicability, and realizes the in-vitro testing of the shunt valve quickly, at low cost and with high authenticity. The present application can quantify the performance of the shunt valve in a real physiological environment.

A 2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7]tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamido]benzamide compound and related derivatives, as well as the use thereof in the preparation of a medicament for treatment and / or prevention of diseases or disorders associated with the circadian rhythm are provided. The compound of the invention is a CLOCK-binding small molecule and also an inhibitor of CLOCK:BMAL1 interaction, and is therefore useful, as pharmaceutical agent, especially in the treatment and / or prevention of disorders associated with the circadian rhythm.

An example computing device includes a memory; and one or more processors coupled to the memory, the one or more processors being configured to: determine a baseline circadian pattern of blood pressure for a patient over a first period of time; determine a subsequent circadian pattern of blood pressure for the patient over a second period of time, the second period of time being after the first period of time; determine one or more differences between the subsequent circadian pattern and the baseline circadian pattern; determine, based on the one or more differences between the subsequent circadian pattern and the baseline circadian pattern, whether the patient is a candidate for denervation therapy; and output, responsive to determining whether the patient is a candidate for the denervation therapy, an indication of whether the patient is or is not a candidate for the denervation therapy.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The present application relates to a kind of circadian rhythm-based circulating water aquaculture fish pond dissolved oxygen mechanism modeling method, including the influence of fish respiration consumption, water surface atmospheric reoxygenation, circulating water flow, mechanical aeration factor on dissolved oxygen dynamic change;According to oxygen transfer equation, considering the influence of the above four factors on fish pond dissolved oxygen, the dissolved oxygen mechanism model of circulating water aquaculture fish pond is established;Combined with oxygen transfer equation and the characteristics of fish respiratory activity changes between day and night, the influence of fish respiratory circadian rhythm on the model is analyzed, and the model is verified.The present application can more accurately reflect the high and low peak value in different time periods and also capture the dynamic changes presented in the whole cycle, and effectively avoid the loss and risk caused by the inaccurate model description to the aquaculture industry in extreme breeding environment or abnormal environment.

The invention provides an illumination system arranged to illuminate a space for rearing a flock of birds, wherein the illumination system comprises: a visible light source configured to emit visible light; an ultraviolet light source configured to emit ultraviolet light; a controller configured to: (i) entrain a circadian rhythm of the flock of birds by controlling the visible light source to emit the visible light for a predetermined period of light, and not to emit the visible light for a predetermined period of dark; (ii) control the ultraviolet light source to emit the ultraviolet light at an ultraviolet light intensity for at least one subperiod within the predetermined period of dark, wherein the ultraviolet light comprises a peak wavelength within the UV-A wavelength range.

The invention belongs to the technical field of biology, and relates to regulation and control of a recent rhythm cycle of soybeans, in particular to application and a method of a GmCRY2a gene in regulation and control of the recent rhythm cycle of the soybeans. According to the research of the invention, two GmCRY2a genes in soybean are knocked out, and a delayed phenotype appears in a recent rhythm period. According to the CRISPR / Cas9 knockout technology constructed by the invention, pure and gmcry2a1a2 mutant soybean plants can be obtained, compared with control soybeans, the recent rhythm of the soybeans is obviously delayed, and the CRISPR / Cas9 knockout technology can be applied to screening of the soybeans suitable for multi-latitude region growth and has a huge application prospect.

The application discloses a method for identifying Klebsiella pneumoniae gene circadian rhythm expression by using a bioluminescence reporting system. The application constructs a recombinant bioluminescence Klebsiella pneumoniae driven by a metabolic gene malate:quinone oxidoreductase mqo promoter (Pmqo), and directly observes the change rule of bacterial gene expression under entrainment and free-running conditions of temperature cycle by monitoring the luminescence characteristics. The luxCDABE gene operon comprises genes for coding luciferase and substrate synthesis enzyme, wherein luxA and luxB code for heterodimer luciferase, luxC, luxD and luxE synthesize aldehyde as a substrate for the luciferase luminescence reaction. The luciferase catalyzes the oxidation of aldehyde to generate visible blue-green light with a wavelength of 450-490 nm. The Lux bioluminescence reporting system has the advantages of not needing to add an exogenous substrate and not affecting the normal physiological functions of the host, and can be applied to the identification of Klebsiella pneumoniae gene circadian rhythm expression.

A 2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7]tetradeca-1,5,7,9-tetraen-8-yl)oxy)acetamidolbenzamide compound and related derivatives, as well as the use thereof in the preparation of a medicament for treatment and / or prevention of diseases or disorders associated with the circadian rhythm are provided. The compound of the invention is a CLOCK-binding small molecule and also an inhibitor of CLOCK:BMALl interaction, and is therefore useful, as pharmaceutical agent, especially in the treatment and / or prevention of disorders associated with the circadian rhythm.

The application discloses a method and system for monitoring light and sleep and improving sleep and circadian rhythm, and aims at the problems of single application scene and function, lagging theory and lack of deep analysis in existing sleep intervention methods, adopts sleep monitoring and light improvement services based on the non-visual effect theory of light, forms the cyclic regulation and feedback of sleep and light monitoring, analysis and evaluation and sleep intervention guidance, guides users to select appropriate lighting lamps, light exposure time and total amount, utilizes light which is strong synchronization and non-contact to improve the circadian rhythm and sleep of personnel, and thus the system can be suitable for the sleep habits of each user and keep a stable circadian rhythm.

Provided herein are methods and devices for determining a personalized circadian rhythm identification and prediction from wearable data comprising: obtaining or having obtained data from one or more wearable devices during one or more daytime and nighttime cycles; using a processor and a machine learning algorithm comprising: determining a daytime threshold and a nighttime threshold from the data obtained during the one or more daytime and nighttime cycles by: temporally segmenting the data; identifying one or more daytime and nighttime boundary by: selecting from at least one of physical activity, heart rate, or sleep status data; temporally segmenting the physical activity, heart rate, or sleep status data to establish a circadian rhythm; using at least one of a 2-mean, 5-mean, or K-nearest neighbor algorithm to determine the one or more daytime and sleeptime boundaries; and identifying and predicting the personalized circadian rhythm.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a preparation method of compound radix bupleuri depression-relieving dropping pills and application of the compound radix bupleuri depression-relieving dropping pills in antidepressant drugs. According to the dropping pill preparation, medicine simplification and optimization are carried out on the basis of Xiaoyao powder, meanwhile, the dissolution rate of insoluble components is improved by adopting a solid dispersion technology, the formability and the medicine loading capacity of the dropping pill are optimized by using a compound matrix and a nano flow aid, and the slow-release coating technology meets the slow-release requirement of circadian rhythmic depression. Meanwhile, the dissolution rate and the stability of effective components are improved, and the sustained release characteristic is achieved, so that the composition is suitable for preventing and treating depression.

The invention relates to a stomach adhesion type double-network hydrogel sensor capable of realizing long-time gastric acid imaging and application of the stomach adhesion type double-network hydrogel sensor. The RHO-PDI probe takes perylene bisimide as a framework and rhodamine B as an acid response unit, pKa is approximately equal to 1.97, and 500-650 nm fluorescence is emitted in gastric acid. The double-network hydrogel is formed by crosslinking sodium polyalginate-calcium ions and polyethylene glycol dithiol-four-arm maleimide, has excellent mechanical strength and gastric wall adhesiveness, and realizes long-term, stable and non-invasive dynamic monitoring of gastric acid and circadian rhythm hormone change tracking.

The present application relates to the technical field of LED lighting, and discloses a light spectrum packaging structure for adjusting day rhythm, which comprises an outer box body, the outer box body comprises a box body and an end cover matched with the box body, characterized in that: a light source box is further arranged in the outer box body, the light source box is a light emitting source, an adjusting mechanism is further arranged in the outer box body, and the adjusting mechanism is used for heat conduction; the adjusting mechanism comprises a protrusion arranged in the box body, a refracting mirror matched with the protrusion is arranged on the light source box, and the refracting mirror is used for refracting light rays. The light spectrum packaging structure for adjusting day rhythm can balance the temperature difference in the outer box body between morning and evening, so that the light source box is not damaged due to overheating or overcooling caused by time period change, the adjusting mechanism is arranged in the outer box body, the adjusting mechanism can collect the temperature in the outer box body in the daytime and release the temperature at night, and the day and night temperatures in the outer box body are balanced.

The application relates to the cross field of computer technology and biomedical engineering, and discloses a miniaturized blood glucose intelligent monitoring and analysis method integrated with edge computing. The method comprises the following steps: collecting glucose concentration and time sequence multi-source physiological signals through a wearable sensor; performing data segmentation and multi-modal feature alignment based on a circadian rhythm; inputting the features into a lightweight biological model obtained through knowledge distillation to perform blood glucose prediction; and combining a memory feedback mechanism to adaptively adjust the reasoning frequency. The system comprises a sensing unit, a preprocessing unit, a lightweight model execution unit and a risk warning unit. While ensuring prediction accuracy, the application compresses the model to within 150,000 parameters, adapts to 512 KB on-chip memory, and realizes low-power, high-stability end-side continuous blood glucose monitoring and warning.

The present invention aims to provide a novel compound which has an OX2R agonist activity.The present invention relates to a cyclopentane compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof has an agonist activity on OX2R and is useful as an agent for the treatment of sleep disorders involving OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to physical diseases, hypersomnia due to psychiatric disorders, hypersomnia due to drugs or substances, circadian rhythm sleep-wake disorder, insufficient sleep syndrome and long sleep) or the like.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

Systems and methods are provided to accurately model nanoparticle deposition in human or animal vasculature while reducing computational costs though a number of specific algorithmic improvements. These methods can be used to virtually evaluate the effects of variations in the nanoparticle configuration (e.g., size, geometry, binding target and / or affinity) and / or timing of delivery (e.g., relative to a patient's circadian rhythm), allowing those properties to be improved in order to increase the nanoparticle dose delivered to an anatomical target and / or to reduce side effects by reducing the total nanoparticle dose used to obtain a specified therapeutically effective level of deposition at the anatomical target. The accuracy and reduced computational cost of these methods allows the simulation to be re-run based on individual patients' data (e.g., MRI or otherwise-obtained maps of vascular geometry), allowing the nanoparticle configuration and / or dosing to be adapted on a per-patient basis.

To provide a novel circadian rhythm regulator. [Solution] A circadian rhythm regulator comprising a phthalide compound having at least one substituent R on a benzene ring as an active ingredient, wherein the at least one substituent R is independently selected from the group consisting of hydroxy, methoxy, ethoxy, propoxy, hydroxymethyl, and acetoxy.

A smart wearable device 100 to determine vascular health and vascular ageing index of a user is described The smart wearable device 100 includes a PPG sensor 202, an accelerometer 204, hydration sensor 206, and temperature sensor 208 to acquire physiological and contextual data of the user. A processing unit 210 filters the PPG waveform using the motion data, hydration level, temperature data, and circadian rhythm to generate a filtered waveform. From this, morphological and temporal features are extracted. Behavioral and physiological modulators, such as sleep-stress score and VO₂ max-based cardio age, are also computed. These inputs form a multi-parametric feature set used by a machine learning model to generate a vascular ageing index.

The invention provides a light control method and system for a smart home, and the method comprises the steps: obtaining the current time and the longitude and latitude information of the smart home; dividing a circadian rhythm period according to the latitude and longitude information, and determining a target circadian rhythm period including the current time; determining a first preset light parameter corresponding to the target circadian rhythm period according to the first corresponding relation; wherein the first corresponding relation is used for representing the corresponding relation between the circadian rhythm time period and the preset light parameters; and adjusting the light of the smart home according to the first preset light parameter. Dynamic adaptation of light parameters of the smart home is achieved, light adjustment and the actual environment of the smart home are completely synchronized, circadian rhythm dislocation during cross-time-zone use is avoided, manual intervention of a user is not needed, the operation burden is reduced, and use convenience is improved; accurate circadian rhythm matching can better accord with the physiological law of the human body, and the use experience of the user is improved.

This invention discloses an intelligent drug scheduling method and system based on drug classification and joint constraint solving, belonging to the field of pharmaceutical information technology. The method includes: 1. Classifying drugs into four categories according to dosing strictness: blood concentration-dependent, local-acting, on-demand, and circadian rhythm-dependent, with each category corresponding to a different drug scheduling strictness strategy; 2. Extracting the independent constraints and inter-drug constraints for each drug, and performing multi-source verification and confidence labeling on the interval requirements; 3. Jointly solving the drug scheduling time for all drugs using the user's lifestyle as an anchor point; 4. Performing four-dimensional verification of the drug scheduling scheme based on interval rationality, dosing conditions, drug compatibility, and executability; 5. Supporting dynamic adjustments such as missed doses, adding medication, and changing medications. This invention solves the problems of existing medication reminder products that independently schedule each drug, cannot detect interval conflicts, do not consider differences in drug classification strictness, and do not anchor to lifestyle, significantly improving the safety and executability of drug scheduling in multi-drug use scenarios.

This invention relates to a method and system for optimizing meal replacement intake time based on circadian rhythms, belonging to the field of nutrition management technology. It includes: collecting basic user information, sleep time, and wake-up time; determining a sleep-wake cycle based on sleep and wake-up times; retrieving user age and gender based on the basic information and dividing the sleep-wake cycle into physiological time periods; retrieving health goals and physical fitness parameters based on the basic information to determine the types of meal replacement foods; determining the initial time for meal replacement intake based on physiological time periods and selecting recommended food types; determining a type-based intake adjustment value based on the recommended food types; adjusting the initial time for meal replacement intake based on the type-based intake adjustment value to obtain a recommended meal replacement intake time and outputting it. This invention improves the efficiency of users in achieving their health goals during nutrition management.

This invention discloses the application of citrus flavonoids (NOB) or SR1078 in the preparation of drugs to improve salivary gland function, particularly in improving the circadian rhythm of salivary glands damaged by ionizing radiation. Oral administration of a specific dose of NOB or SR1078 can significantly promote salivary gland function. Furthermore, it does not interact with other drugs with anti-inflammatory or regenerative functions. It can be administered as a single dose or multiple times consecutively; it can be administered after injury, and this flexible administration method does not affect the tumor radiotherapy process.

Provided are compounds of the Formula II, and salts, hydrates and solvates thereof:wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and / or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and / or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and / or conditions in which CK2α activity is implicated.